On April 8, 2024, Ian Shakil, Chief Strategy Officer of Augmedix Inc (AUGX, Financial), sold 89,167 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing.
Augmedix Inc is a company that specializes in using technology to transform the documentation of patient health data. By leveraging artificial intelligence and other advanced technologies, Augmedix aims to improve the accuracy and efficiency of medical record-keeping, thereby enhancing the overall healthcare delivery process.
Over the past year, the insider has sold a total of 360,557 shares and has not made any purchases. The recent sale by Ian Shakil is part of a broader pattern of insider transactions at Augmedix Inc. In the past year, there have been 3 insider buys and 5 insider sells.
On the date of the insider's recent sale, shares of Augmedix Inc were trading at $4.01, giving the company a market cap of approximately $197.883 million.
The stock's price-to-GF-Value ratio stands at 0.83, with a GuruFocus Value of $4.85, indicating that Augmedix Inc is considered Modestly Undervalued based on its GF Value. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which factors in historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling and buying activities at Augmedix Inc.
The GF Value image provides a visual representation of the stock's valuation relative to its GuruFocus Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
